ClinicalTrials.gov Identifier: NCT04951076 : May 3, 2023 & NCT 05193409 , both awaiting updates and or further trials .which from previous ANNs. should be imminent The ASX delisting and status of the trials is not ,IMO, unrelated . The benefit of delisting and doing a reverse consolidation( 180 to 1 ASX) share, may benefit US investors in BNOX and perhaps make the financials more attractive to Merck etc
The $ question is whether BNOX will disclose trial results and status of FDA discussions before ASX investors have to choose between selling or following management to US . I would expect the management will try to pickup discounted ASX shares caused by the uncertainty Any material disclosure of trial results or FDA discussions will be delayed until after ASX delisting IMO.
BNO Price at posting:
1.3¢ Sentiment: Hold Disclosure: Held
